Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
Avastin® is a humanized monoclonal antibody that binds to vascular endothelial growth factor
(VEGF). VEGF plays an important role in the growth of both normal and abnormal blood vessels.
Avastin® is designed to prevent or slow down the growth of cancer cells by blocking the
effects of VEGF.
Docetaxel and carboplatin are standard chemotherapy drugs that have been approved by the FDA
for the treatment of NSCLC. Docetaxel and carboplatin are designed to work by stopping the
division of cancer cells.
If you are found to be eligible, you will begin receiving Avastin®, docetaxel, and
carboplatin. Avastin®, carboplatin, and docetaxel will be given by vein once every 3 weeks.
The first dose of Avastin® will be given over 90 minutes. The second dose of Avastin® will be
given over 60 minutes. All other doses of Avastin® will be given over 30 minutes. Carboplatin
and docetaxel will always be given over 30 minutes. They will be given on the same day every
3 weeks (1 cycle). You may receive up to 6 cycles of treatment. You will receive standard
premedication with dexamethasone to help decrease the risk of side effects. Dexamethasone
will be taken before you receive your docetaxel infusion.
During the study, you will have blood tests (about 2 teaspoons) every 3 weeks to look at your
blood counts. These samples will be used only for routine lab tests. You will be seen by a
physician every 3 weeks and given a physical exam. Your blood pressure will be monitored, and
you will be asked about any side effects you are experiencing. A performance status
evaluation will also be done. In addition, you will have a urine test every 2 cycles of
treatment.
After 2 cycles of treatment (6 weeks), you will have a chest x-ray and computerized
tomography (CT) or magnetic resonance imaging (MRI) scan to evaluate the status of the
disease. These will be repeated every 2 cycles. Your continued participation in this study
depends on how your cancer responds to the study drugs. Your doctor may decide to take you
off this study if you experience significant side effects or your medical condition worsens.
You may continue receiving bevacizumab for as long as your cancer responds to study
treatment.
You will be followed-up on by phone or at routine clinic visits for at least 12 months to
monitor your condition and disease status.
This is an investigational study. Avastin® has been approved by the FDA for the treatment of
colorectal cancer. Docetaxel and carboplatin are FDA approved and commercially available. The
use of these drugs together in this study is experimental. A total of 50 patients will take
part in this study. All participants will be enrolled at M. D. Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
| Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
| Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
| Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
| Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |